5-MTP ameliorates arterial denudation-induced intimal hyperplasia via opposing effects on vascular endothelial and smooth muscle cells

Cardiovascular diseases remain the leading cause of morbidity and mortality worldwide, particularly among older adults. Despite the advent of medical technology, restenosis is still an issue after interventional procedures. Tryptophan metabolite 5-methoxytryptophan (5-MTP) has recently been shown to protect against systemic inflammatory responses. Dr. Shaw-Fang Yet from the Institute of…

Continue reading

Efficient treatment of recurrent hepatitis B complications can save lives and money: NHRI researchers

December 9, 2019 Scientists with Taiwan’s National Health Research Institutes (NHRI) and National Taiwan University Hospital, with the support of the Taiwan Cooperative Oncology Group (TCOG), have determined that prophylactic antiviral therapy for lymphoma patients will be essential to optimizing preventative strategies and the allocation of medical resources. In hepatitis…

Continue reading

Frequent drinking associated with risk of head and neck cancer: NHRI study November 25, 2019   Higher frequency and amount of alcohol use are associated with an increased head and neck cancer risk, according to the results of a study conducted by the National Health Research Institutes’ National Institute of…

Continue reading

Do you have social jet lag? Rhythm, a new smartphone app, helps you understand your sleep rhythms

November 18, 2019 A free new smartphone application, Rhythm, developed by Dr. Yu-Hsuan Lin of the National Research Health Institutes, is a breakthrough for measuring sleep patterns that can help people improve their sleep health and consequently their overall quality of life. Its features represent an important advance over what…

Continue reading

Substance in honeybee propolis may be useful in treating prostate cancer: new study

November 11, 2019   Dysregulation of androgen receptor signaling is one of the causes promoting the development of prostate cancer, benign prostate hyperplasia (BPH), and androgenetic alopecia. The prescription drugs for these diseases either block the production of androgen or inhibit the binding between androgen and androgen receptor (AR). However,…

Continue reading

NHRI Taiwan launches G2020 Population Genomics Pilot, partnering with Illumina on an Operational Architecture for Population Genomics

November 6, 2019 Pilot effort will sequence 10,000 genomes by end of 2020, with the goal of embedding genome sequencing in the health system by 2025. TAIPEI: The National Health Research Institutes (NHRI) of Taiwan today announced that it is taking an effort to embed whole genome and exome sequencing…

Continue reading

NHRI’s technology behind a novel vaccine for respiratory syncytial virus was transferred to BioChina, leading to the 2018 Outstanding Tech Transfer Award from the Ministry of Science and Technology

September 2, 2019 (for immediate release) Vaccine research at the National Health Research Institutes (NHRI) of Taiwan has led to an award from the Ministry of Science and Technology for Outstanding Technology Transfer. This helps reconfirm NHRI’s essential role in Taiwan’s biomedicine sector. The technology for a novel vaccine for…

Continue reading

What I learned from Prof. Kim Nasmyth’s closing remarks at the “Evolution, Structure and function of Chromosomes High Order Structure” Conference

I attended the four-day Pasteur Institute conference titled “Evolution, Structure and /function of Chromosomes High Order Structure” in memory of Francois Jacob from June 4 to 7. I was very fortunate to have this opportunity not only to learn the fundamentals about eukaryotic and prokaryotic chromosomes but also to add…

Continue reading

NHRI researchers conduct a benchmark dose study of prenatal exposure to DEHP and behavioral problems in children

Prenatal exposure to di(2-ethylhexyl) phthalate (DEHP) has been reported to be associated with adverse effects on neurodevelopment that yield behavior syndromes in young children with an estimated median exposure lower than the currently recommended tolerable daily intake (TDI) of 50 μg/kg_bw/day and reference dose (RfD) of 20 μg/kg_bw/day. Given the…

Continue reading

NHRI researchers reports the effect of cetuximab-based sequential therapy as a primary treatment in advanced oral squamous cell carcinoma

Head and neck cancer — including cancers of the oral cavity, oropharynx, hypopharynx, and larynx — is the 4th leading cancer among Taiwanese men. Despite the progressions in the treatment of advanced oral squamous cell carcinoma (OSCC), its prognosis remain poor. Cetuximab (Erbitux®) is an epidermal growth factor receptor (EGFR)…

Continue reading